CALGARY, May 8, 2020 – Equity Health Services announces a strategic alliance to help Canadian governments, private sector businesses, and Indigenous communities increase COVID-19 testing capacity using reliable, high-quality testing technology.
Equity’s strategic partner Seegene Inc., a global leader in biotechnology, has provided 10 million COVID-19 tests to 60 countries around the world. The Seegene Allplex™ 2019-nCoV Assay represents a significant percentage of all international COVID-19 testing efforts.
Developed using AI-based design technology, the test combines both best-in-class performance (sensitivity/specificity) and high throughput automation (up to 750 accurate tests/day). These components are particularly critical in halting large-scale outbreaks in long-term care homes and sectors such as construction, manufacturing, agriculture, healthcare, and hospitality.
“Wide-spread, rapid testing is a fundamental tool in the fight against COVID-19, and becomes even more important as social distancing protocols start to loosen,” says Art Agolli, Founder and CEO of Equity Health Services. “This alliance, part of the rapid expansion of our healthcare services portfolio, helps us provide solutions for testing capacity challenges across the country.”
“We are pleased to be partnering with Equity Health Services in the fight against this virus,”says Dr. Jong-Yoon Chun, CEO of Seegene. “We are very proud that our cutting edge diagnostic technologies can play an important role in helping to save lives.”
About Equity Health Services
Equity Health Services provides strategic and operational healthcare solutions for governments, Indigenous communities, and a diverse range of private sector industries including oil and gas, manufacturing, construction, hospitality, and mining. Our customized, innovative offerings range from diagnostic solutions to the delivery of mobile health services in remote, challenging, or under-resourced locations. www.equityhealthservices.com
About Seegene
Seegene (KQ : 096530) is a global pioneer in symptom-based in vitro molecular diagnostics focusing on advancing science to develop multiplex molecular technologies and to manufacture multiplex in vitro diagnostic devices and reagents. Seegene’s core enabling power is the passion for wide spreading of multiplex molecular diagnostics to improve the quality of life and health of people. Using its innovative proprietary technologies, Seegene has been making considerable contributions to giving the most economic and clinic-friendly molecular diagnostic solutions for infectious diseases, genetics, pharmacogenetics, and oncology. www.seegene.com
